|Videos|March 30, 2022
Risk Models and Prognostic Factors
Author(s)Robert S. Alter, MD
Robert Alter, MD comments on the use of prognostic models for determining risk status and informing treatment options in patients with RCC.
Advertisement
Episodes in this series
Advertisement
Related to this article
“What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.
ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in metastatic urothelial carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
3
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
4
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
5